infohep news

• Transplants from donors with HCV

  Pre- and post-transplant antiviral treatment prevents hepatitis C transmission in all organ recipients, Canadian study finds

  Keith Alcorn / 14 November 2019

  Adding a cholesterol-lowering drug to direct-acting antivirals prevented hepatitis C infection in all recipients of organ transplants from donors with hepatitis C, Jordan Feld, Research Director, Toronto Centre for Liver Disease, reported at ...

• Coalition of liver associations calls for simplifying hepatitis C care

  Liz Highleyman / 13 November 2019

  Leaders of liver disease associations from Europe, the United States, Latin America and Asia issued a global call to action at the Liver Meeting this week in Boston, aiming to advance toward ...

• New and experimental treatments for hepatitis B

  Therapeutic hepatitis B vaccine may lead to functional cure

  Liz Highleyman / 13 November 2019

  An experimental called NASVAC, which targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen (HBsAg) levels, according to study presented this week at the ...

• Experimental treatments for NASH/NAFLD

  Emricasan and selonsertib fail to improve fibrosis in people with NASH

  Liz Highleyman / 12 November 2019

  A pair of experimental therapies for non-alcoholic steatohepatitis (NASH) failed to offer notable improvements in controlled clinical trials, despite having shown promising effects on liver biomarkers in earlier studies. Dr. Stephen Harrison ...

• Hepatocellular carcinoma (HCC)

  When is the right time to treat hepatitis C in people with liver cancer?

  Keith Alcorn / 27 October 2019

  Direct-acting antiviral treatment for hepatitis C need not be delayed until the completion of treatment for hepatocellular carcinoma (HCC; liver cancer), but people with hepatitis C need to be warned of a ...